Published in Primary Care

$1 or Mystery Box - Presbyopia Edition

This is editorially independent content supported by advertising from Orasis Pharmaceuticals
2 min read

Find out what your fellow optometrists know about presbyopia by playing the game, $1 or Mystery Box!

$1 or Mystery Box - Presbyopia Edition
Attendees at this year’s Southern Council of Optometrists (SECO) meeting were greeted with a surprise: a quick game of $1 or Mystery Box!
The gifts weren’t free, though — recipients had to face the challenge of answering a question about presbyopia drops!

Test Your Knowledge on Presbyopia Myths

Do you know why the following are important to know before prescribing presbyopia drops?

How do you differentiate between all the different types of presbyopia drops available?

A Pharmaceutical Approach To Presbyopia Treatment

The pharmacological approach to treatment provides a local, non-invasive, and reversible treatment for presbyopia. Generally, these eye drops cause miosis and enhance depth of focus through a pinhole effect. Before prescribing the miotic pilocarpine, it is essential to assess the risk of retinal detachment.1
Proper patient selection is crucial. The refractive profiles that typically respond best include emmetropes, mild myopes, low hyperopes, pseudophakic patients, and those who have undergone post-refractive surgery.
Not all drops are created equal. QLOSI (pilocarpine ophthalmic solution, 0.4%) is the lowest FDA-approved pilocarpine concentration.2 It is also the only eye drop with a single-digit rate of ocular adverse events3 while having minimal ciliary muscle effect.3
Other FDA-approved options include pilocarpine ophthalmic solution, 1.25% (VUITY), aceclidine ophthalmic solution, 1.44% (VIZZ), and carbachol and brimonidine tartrate ophthalmic solution, 2.75%/0.1% (YUVEZZI).
  1. Grzybowski A, Kapitanovaite L, Zemaitiene R. An updated systematic review of pharmacological treatments for presbyopia. Adv Ophthalmol Pract Res. 2024;4(4):220-225. Published 2024 Sep 3. doi:10.1016/j.aopr.2024.09.001
  2. Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: Pooled results of the near phase 3 randomized, clinical trials. Clinical Therapeutics. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  3. Dillon M. New data demonstrate QlosiTM is pupil selective with ciliary muscle movement no different than a balanced Salt Solution (BSS) control. Orasis. January 27, 2026. Accessed March 26, 2026. https://www.orasis-pharma.com/new-data-demonstrate-qlosi-is-pupil-selective-with-ciliary-muscle-movement-no-different-than-a-balanced-salt-solution-bss-control/.
Eyes On Eyecare Editorial Team
About Eyes On Eyecare Editorial Team

Led by Editor-in-Chief Eleanor Gold, PhD, Eyes On Eyecare is a digital publication that provides clinical and career education to the young generation of optometrists and ophthalmologists. We work with eyecare professionals to create compelling, educational content available for free to all those in the eyecare industry. To learn more about our team, values, and other projects, visit our About page.

Eyes On Eyecare Editorial Team